HealthMerck’s experimental skin disease drug succeeds in mid-stage study

Merck said on Wednesday that its experimental drug significantly reduced inflammatory skin lesions in patients with a chronic skin disease, meeting the main goal of a mid-stage study.

Merckskin diseaseclinical trial

RReuters★★☆☆☆2026-09-30 14:45Original